Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$806.06 USD

806.06
3,726,192

-0.08 (-0.01%)

Updated Nov 5, 2024 04:00 PM ET

Pre-Market: $812.02 +5.96 (0.74%) 9:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Amgen's (AMGN) Q4 Earnings Top Estimates, Product Sales Fall

by Zacks Equity Research

Amgen (AMGN) beats Q4 estimates for earnings but misses the same for sales. Higher Other Revenue for manufacturing Eli Lilly's COVID-19 antibody boost sales growth.

Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder

by Zacks Equity Research

The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.

The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer

by Zacks Equity Research

AbbVie, Merck, Eli Lilly, Novartis and Pfizer are included in this analyst blog.

How Will Pfizer's (PFE) Key Drugs Perform in Q4 Earnings?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 vaccine are likely to have driven sales in the fourth quarter.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program

by Kinjel Shah

AbbVie (ABBV), Merck (MRK), Eli Lilly (LLY) and Novartis (NVS) report fourth-quarter results. Pfizer (PFE) ends vupanorsen development.

Sanofi (SNY) Q4 Earnings Beat, Vaccines Hurt Sales Growth

by Zacks Equity Research

Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.

Eli Lilly (LLY) Q4 Earnings Miss, COVID Therapies Aid Sales

by Zacks Equity Research

Eli Lilly (LLY) misses earnings estimates in the fourth quarter while revenues beat the same. Stock down in pre-market trading.

Merck (MRK) Q4 Earnings & Sales Beat, COVID Drug Adds $952M

by Zacks Equity Research

Merck (MRK) beats Q4 estimates for earnings and sales. The company anticipates robust growth in revenues and income to continue in 2022.

Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates

by Zacks Equity Research

Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

Drug/Biotech Stocks Earnings on Feb 3: BIIB, LLY & MRK

by Zacks Equity Research

Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.

Novartis (NVS) Q4 Earnings & Sales Miss, Sandoz Review Ongoing

by Zacks Equity Research

Novartis (NVS) reports dismal results for the fourth quarter. Key brands maintain momentum but the generics business remains weak.

Eli Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) fourth-quarter sales.

Pfizer (PFE) Ends Vupanorsen Development, Returns Rights to Ionis

by Zacks Equity Research

Pfizer (PFE) returns development rights to Ionis for the investigational antisense therapy, vupanorsen.

Pfizer (PFE) Lorviqua Gets EU Nod for First-Line Lung Cancer

by Zacks Equity Research

The European Commission approves label expansion of Pfizer's (PFE) Lorviqua as a first-line treatment for ALK-positive non-small cell lung cancer.

Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema

by Zacks Equity Research

While Eli Lilly (LLY) and Incyte (INCY) have decided to discontinue the development of JAK inhibitor Olumiant in lupus indication, they expect a complete response letter from the FDA for Olumiant in atopic dermatitis.

Pfizer (PFE) Gets CHMP Recommendation for COVID Pill Paxlovid

by Zacks Equity Research

Pfizer's (PFE) oral COVID-19 drug, Paxlovid, gets recommendation from the CHMP for its authorization in Europe for treating mild-to-moderate COVID-19 in patients at increased risk of hospitalizations.

ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates

by Zacks Equity Research

ResMed's (RMD) Q2 earnings meet estimates, with robust demand for sleep and respiratory care devices driving the top line.

Merck (MRK) Keytruda Gets EU Nod for Expanded Kidney Cancer Use

by Zacks Equity Research

Following EU nod, Merck's (MRK) Keytruda is now approved as an adjuvant therapy for renal cell carcinoma in certain adult patients who are at an increased risk of recurrence, following nephrectomy.

Is a Beat Likely for AbbVie (ABBV) This Earnings Season?

by Zacks Equity Research

AbbVie's (ABBV) fourth-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics. Investors are likely to focus on any update related to the guidance for 2022.

Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed the most recent trading day at $237.86, moving -0.67% from the previous trading session.

The Zacks Analyst Blog Highlights: Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck

by Zacks Equity Research

Eli Lilly, Regeneron Pharmaceuticals, Pfizer and Merck are included in this blog.

The Zacks Analyst Blog Highlights: Pfizer, Merck, Eli Lilly, Regeneron and Gilead

by Zacks Equity Research

Pfizer, Merck, Eli Lilly, Regeneron and Gilead are included in this analyst blog.

SAB Biotherapeutics (SABS) Posts Data From COVID Treatment Study

by Zacks Equity Research

Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PJP

FDA Limits Use of Regeneron & Lilly's COVID Antibody Cocktails

by Zacks Equity Research

The FDA modifies EUA for COVID-19 antibody cocktail drugs of Regeneron (REGN) and Lilly (LLY), limiting their use to treat individuals with COVID-19 infection from non-Omicron variants.